2d:I[856015,["/_next/static/immutable/chunks/1xzisbplk9czp.js","/_next/static/immutable/chunks/3j2i1faptc_-9.js","/_next/static/immutable/chunks/0fma7nlq6immz.js","/_next/static/immutable/chunks/08tq8rmv423j5.js","/_next/static/immutable/chunks/1chr5wkk3j58k.js","/_next/static/immutable/chunks/37kmmh_zm4dov.js","/_next/static/immutable/chunks/311zvdjfxff-f.js","/_next/static/immutable/chunks/1a_hqhrsle_n_.js"],"default"] 2e:T6adc,

Summary Table

Category	Details
Risk Factors	Asbestos exposure (occupational: shipyard workers, construction, insulation, mining, plumbing); latency period of 20 to 50 years; prior radiation therapy to the chest; erionite exposure (volcanic mineral fiber, rare)
Etiology	Chronic irritation and DNA damage of mesothelial cells by inhaled asbestos fibers (amphibole type carries highest risk). Not caused by smoking alone.
Patient Presentation	Older male (typically 60s-70s) with insidious dyspnea, nonpleuritic chest pain, and unintentional weight loss. History of occupational asbestos exposure decades ago.
Classic Physical Exam	Unilateral pleural effusion (typically right-sided), decreased breath sounds, dullness to percussion, reduced chest expansion on the affected side. Late findings: palpable chest wall mass, contralateral mediastinal shift.
Key Diagnostic Results	CT: pleural thickening with nodularity, encasing the lung ("rind-like"). Pleural fluid: exudative, often hemorrhagic. Biopsy with immunohistochemistry is confirmatory. Calretinin (+), WT-1 (+), CK5/6 (+), CEA (-), TTF-1 (-).
Management	Chemotherapy with pemetrexed + cisplatin (first-line). Surgery (pleurectomy/decortication or extrapleural pneumonectomy) in select early-stage cases. Multimodal approach for resectable disease.
Keywords	"Asbestos exposure," "shipyard worker," "pleural thickening," "hemorrhagic pleural effusion," "calretinin positive," "psammoma bodies," "pleural plaques on imaging"

1. Pathophysiology

Mesothelioma is a primary malignancy arising from the mesothelial cells that line the pleural, peritoneal, pericardial, or tunica vaginalis surfaces. The pleura is the most commonly affected site, accounting for roughly 80% of cases.

The disease is driven almost exclusively by asbestos fiber inhalation. Among asbestos subtypes, amphibole fibers (crocidolite, amosite) are far more carcinogenic than serpentine fibers (chrysotile) because of their rigid, needle-like shape. Once inhaled, these fibers penetrate deep into the distal airways and migrate to the pleural surface. Macrophages attempt to phagocytose the fibers but fail due to the fibers' length, resulting in frustrated phagocytosis. This triggers a chronic inflammatory cascade with persistent release of reactive oxygen species (ROS) and reactive nitrogen species (RNS), which cause direct DNA damage, chromosomal aberrations, and activation of oncogenic signaling pathways such as NF-kB and PI3K/AKT.

A hallmark of asbestos-related carcinogenesis is the inactivation of tumor suppressor genes, particularly BAP1 (BRCA1-associated protein 1) and CDKN2A (p16). Loss of BAP1 function is found in approximately 60% of mesotheliomas and serves as both a diagnostic and prognostic marker. Germline BAP1 mutations also explain rare familial clustering of mesothelioma cases.

The extremely long latency period of 20 to 50 years is a direct reflection of this slow, cumulative process of inflammation, mesothelial cell injury, and eventual malignant transformation. This is why the classic vignette presents an elderly patient whose asbestos exposure occurred decades earlier.

The tumor grows along the pleural surface in a circumferential, rind-like pattern, progressively encasing and restricting the lung rather than forming a discrete parenchymal mass. This explains the insidious onset of dyspnea (from restrictive physiology and effusion) and chest wall pain (from direct tumor invasion of the intercostal nerves and chest wall structures). The associated pleural effusion is exudative and frequently hemorrhagic due to tumor vascularity and pleural surface erosion.

It is important to distinguish that asbestos exposure causes both benign and malignant pleural disease. Benign pleural plaques (calcified or noncalcified) are a marker of prior asbestos exposure but are not premalignant. They do not transform into mesothelioma. However, their presence on imaging confirms the exposure history and should raise clinical suspicion.

Notably, smoking does not independently cause mesothelioma. Smoking synergizes with asbestos to dramatically increase the risk of bronchogenic lung carcinoma (multiplicative risk), but this synergy does not apply to mesothelioma. This distinction is heavily tested.

2. Classification and Clinical Manifestation

Histologic Subtypes

Subtype	Frequency	Key Features	Prognosis
Epithelioid	~60%	Most common; tubular or papillary growth pattern; resembles adenocarcinoma; psammoma bodies may be seen	Best prognosis; most responsive to therapy
Sarcomatoid	~15-20%	Spindle cell morphology; resembles fibrosarcoma; highly aggressive	Worst prognosis; poor response to chemotherapy
Biphasic (Mixed)	~20-25%	Contains both epithelioid and sarcomatoid components; requires at least 10% of each component for classification	Intermediate prognosis; depends on the proportion of sarcomatoid component

Anatomic Classification

Site	Frequency	Characteristic Presentation
Pleural	~80%	Dyspnea, chest pain, unilateral pleural effusion, weight loss
Peritoneal	~15-20%	Abdominal distension, ascites, abdominal pain, bowel obstruction; often diagnosed at a more advanced stage
Pericardial	~1%	Pericardial effusion, tamponade, constrictive physiology
Tunica vaginalis	<1%	Hydrocele or scrotal mass in elderly males with asbestos history

Clinical Staging (Simplified)

Stage	Description	Resectability
I	Tumor confined to ipsilateral parietal pleura	Potentially resectable
II	Invasion into ipsilateral lung parenchyma or diaphragm; or involvement of ipsilateral visceral pleura	Potentially resectable
III	Locally advanced: invasion into chest wall, mediastinal structures, or ipsilateral lymph nodes	Generally unresectable
IV	Distant metastases or contralateral pleural involvement	Unresectable; palliative care

3. Diagnostic Workup

Test	Role	Key Findings
Chest X-ray	Initial screening	Unilateral pleural effusion, pleural thickening, calcified pleural plaques (indicate asbestos exposure)
Contrast-enhanced CT chest	Best initial imaging test	Nodular or circumferential pleural thickening ("rind-like"), pleural effusion, involvement of fissures, mediastinal invasion
Thoracentesis	Initial diagnostic step for effusion	Exudative, often hemorrhagic fluid; cytology has low sensitivity (~30%)
CT-guided or thoracoscopic biopsy	Most accurate (gold standard)	Tissue for histology and immunohistochemistry
Immunohistochemistry panel	Confirmatory and essential for distinguishing from adenocarcinoma	Calretinin (+), WT-1 (+), CK5/6 (+), D2-40 (+); CEA (-), TTF-1 (-), MOC-31 (-), BerEP4 (-)
PET-CT	Staging	Metabolic activity of pleural disease; detection of distant metastases
Pulmonary function tests	Preoperative assessment	Restrictive pattern; determines surgical candidacy

When a vignette presents an older patient with a remote history of asbestos exposure and a unilateral pleural effusion, the first step is imaging. A chest X-ray will typically show a large unilateral effusion, and you may notice pleural thickening or calcified plaques. However, chest X-ray alone cannot confirm mesothelioma.

The best initial imaging study is a contrast-enhanced CT of the chest. The hallmark CT finding is circumferential, nodular pleural thickening that encases the lung, often described as a "rind" or "sheet-like" growth along the pleural surface. This pattern is distinct from the discrete peripheral mass seen in bronchogenic carcinoma. Additional CT findings include involvement of the interlobar fissures, mediastinal pleural thickening, and ipsilateral volume loss.

The next step is thoracentesis to characterize the effusion. The fluid is exudative by Light's criteria and frequently hemorrhagic. However, pleural fluid cytology has poor sensitivity (approximately 26 to 32%), because mesothelial cells are difficult to classify as benign or malignant on cytology alone. A negative cytology does not rule out mesothelioma.

Because cytology is unreliable, the gold standard for diagnosis is tissue biopsy, ideally obtained via video-assisted thoracoscopic surgery (VATS). This allows direct visualization of the pleural surface and acquisition of adequate tissue. CT-guided percutaneous biopsy is an alternative but yields smaller samples.

The biopsy specimen must undergo immunohistochemistry (IHC), which is essential for two reasons: confirming mesothelial origin and excluding metastatic adenocarcinoma to the pleura.

The classic IHC profile for mesothelioma:

Marker	Mesothelioma	Lung Adenocarcinoma
Calretinin	Positive	Negative
WT-1	Positive	Negative
CK5/6	Positive	Negative
D2-40 (podoplanin)	Positive	Negative
CEA	Negative	Positive
TTF-1	Negative	Positive
MOC-31	Negative	Positive
BerEP4	Negative	Positive
BAP1 loss	Present in ~60%	Retained

The mnemonic to recall: mesothelioma is calretinin-positive and CEA-negative, while adenocarcinoma is the opposite.

Once the diagnosis is confirmed, PET-CT is used for staging to evaluate for distant metastatic disease and to assess the contralateral hemithorax.

4. Management and Treatment

Clinical Scenario	Management
Early-stage, resectable (Stage I-II), good performance status	Multimodal: surgery + chemotherapy +/- radiation
Surgery options	Pleurectomy/decortication (P/D) preferred over extrapleural pneumonectomy (EPP) due to lower morbidity
First-line chemotherapy	Pemetrexed 500 mg/m^2 + Cisplatin 75 mg/m^2, every 21 days, for 6 cycles
If cisplatin-intolerant	Pemetrexed + Carboplatin (AUC 5)
Immunotherapy (advanced/unresectable)	Nivolumab + Ipilimumab (first-line for unresectable, non-epithelioid or epithelioid subtypes)
Symptomatic pleural effusion	Thoracentesis for immediate relief; pleurodesis (talc) for recurrent effusions
Advanced/unresectable (Stage III-IV)	Systemic chemotherapy or immunotherapy; palliative radiation for pain; best supportive care

Acute symptomatic management begins with addressing the pleural effusion. Large, symptomatic effusions causing dyspnea should be drained via therapeutic thoracentesis. For patients with recurrent effusions, talc pleurodesis (chemical sclerosing via thoracoscopy or bedside slurry) or placement of an indwelling pleural catheter provides long-term palliation.

For patients with early-stage, resectable disease and adequate cardiopulmonary reserve, the treatment of choice is a multimodal approach combining surgery with systemic chemotherapy. The preferred surgical procedure has shifted toward pleurectomy/decortication (P/D), which removes the visceral and parietal pleura while preserving the lung. This carries lower perioperative mortality compared to the more radical extrapleural pneumonectomy (EPP), which removes the lung, pleura, diaphragm, and pericardium en bloc. EPP is now reserved for highly selected cases.

The cornerstone of systemic therapy is pemetrexed combined with cisplatin. Pemetrexed (500 mg/m^2 IV) plus cisplatin (75 mg/m^2 IV) is administered every 21 days for up to 6 cycles. Patients receiving pemetrexed must be supplemented with folic acid (400 to 1000 mcg daily, starting 7 days before the first dose) and vitamin B12 (1000 mcg IM, given at least 7 days before the first cycle and every 9 weeks thereafter) to reduce the risk of severe myelosuppression and mucositis. Dexamethasone premedication (4 mg twice daily for 3 days, starting the day before infusion) is also standard to prevent skin rash.

For patients who cannot tolerate cisplatin (e.g., renal insufficiency, significant neuropathy), carboplatin (AUC 5) is substituted.

A landmark advancement in treatment is the use of immune checkpoint inhibitors. The combination of nivolumab (3 mg/kg every 2 weeks) plus ipilimumab (1 mg/kg every 6 weeks) has demonstrated an overall survival benefit compared to chemotherapy alone, particularly in patients with non-epithelioid (sarcomatoid or biphasic) histology. This regimen is now a first-line option for unresectable mesothelioma.

Radiation therapy in mesothelioma has a limited curative role due to the diffuse nature of the tumor. It is primarily used as adjuvant therapy post-surgery to reduce local recurrence, or as palliative radiation for chest wall pain or painful procedural tract metastases (prophylactic irradiation of biopsy/drain sites remains debated).

There is no established role for prophylactic treatment in asymptomatic individuals with a history of asbestos exposure. These patients should undergo clinical surveillance with periodic imaging and symptom monitoring.

5. Differential Diagnosis and Distractors

Differential	Why It Is Similar	Key Discriminator
Metastatic adenocarcinoma to the pleura	Pleural effusion + pleural thickening in an older patient; most common mimic	IHC: TTF-1 (+), CEA (+), calretinin (-). Mesothelioma is calretinin (+), CEA (-). Adenocarcinoma tends to form discrete nodules rather than diffuse rind-like thickening.
Asbestosis (pulmonary fibrosis)	Same exposure history; dyspnea; pleural plaques on imaging	Asbestosis causes bilateral lower lobe interstitial fibrosis (reticular opacities, honeycombing). It is a parenchymal disease, not a pleural malignancy. No pleural mass or nodular thickening.
Benign asbestos pleural effusion (BAPE)	Asbestos-exposed patient with a unilateral exudative, sometimes hemorrhagic effusion	BAPE is a diagnosis of exclusion. Effusion resolves spontaneously. No pleural thickening or nodularity on CT. Biopsy shows no malignant cells. Requires follow-up to ensure mesothelioma does not develop.
Empyema	Unilateral pleural effusion with pleural thickening ("split pleura sign")	Empyema presents with fever, leukocytosis, and purulent fluid with low glucose and low pH. No asbestos exposure history. Pleural thickening is smooth, not nodular.
Bronchogenic carcinoma with pleural involvement	Lung mass + pleural effusion in a smoker	Bronchogenic carcinoma typically shows a discrete parenchymal mass or hilar lesion. IHC profile differs (TTF-1 positive for adenocarcinoma). Smoking is a risk factor for lung cancer but not for mesothelioma.
Tuberculous pleuritis	Unilateral exudative effusion, pleural thickening, weight loss	TB effusion is lymphocyte-predominant with elevated adenosine deaminase (ADA). Pleural biopsy shows caseating granulomas. Patient is often younger and from an endemic area.
Fibrous tumor of the pleura (solitary fibrous tumor)	Pleural-based mass; can cause dyspnea	Solitary fibrous tumor is a localized, pedunculated mass arising from the pleura, not diffuse thickening. It may cause hypoglycemia (Doege-Potter syndrome) or clubbing. Usually benign.

6. Traps and High-Yield Pearls

The most common way students get questions on mesothelioma wrong is by confusing it with bronchogenic lung carcinoma or by incorrectly associating smoking with mesothelioma risk. When a vignette describes a patient with asbestos exposure and a pleural effusion, students sometimes select "lung cancer" because they recall the asbestos-smoking synergy. The critical distinction: the asbestos-smoking multiplicative risk applies to bronchogenic carcinoma, not mesothelioma. Mesothelioma risk is driven by asbestos alone, and smoking does not increase mesothelioma risk.

A second common trap involves the diagnostic approach. Students often select pleural fluid cytology as the confirmatory test. While thoracentesis is an appropriate early step, cytology has notoriously poor sensitivity for mesothelioma. The correct answer for the gold standard is always tissue biopsy with immunohistochemistry. If a question asks for the "next best step" after a negative cytology in a patient with suspicious imaging, the answer is thoracoscopic biopsy, not repeat thoracentesis.

Third, students may confuse pleural plaques with mesothelioma. Calcified pleural plaques are a marker of prior asbestos exposure and are the most common radiographic manifestation of asbestos-related disease. However, plaques are benign and do not undergo malignant transformation. Their presence should raise suspicion for asbestos-related disease but does not constitute a diagnosis of mesothelioma.

Fourth, remember the IHC panel. When a question presents a pleural biopsy and asks you to distinguish mesothelioma from metastatic adenocarcinoma, the discriminator is: calretinin-positive and CEA-negative points to mesothelioma; calretinin-negative and CEA-positive (with TTF-1 positive) points to adenocarcinoma. This is one of the most consistently tested immunohistochemistry panels.

Finally, regarding treatment, the testable pearl is the pemetrexed-cisplatin combination as first-line chemotherapy and the mandatory supplementation with folic acid and vitamin B12 to prevent toxicity. Forgetting supplementation is a tested pitfall, as pemetrexed without folate supplementation causes severe myelosuppression.

The core competency being tested across mesothelioma questions is the ability to integrate an occupational exposure history with characteristic imaging and pathologic findings, correctly sequence the diagnostic workup from imaging through biopsy, and apply the immunohistochemical profile to distinguish this tumor from its closest mimics.

1e:["$","$L2d",null,{"article":{"id":"0ee19622-01f5-47cc-a184-fac652bc0697","title":"Mesotelioma","content":"$2e","category":"Respirologi","created_at":"2026-07-02T00:52:23.830579+00:00","status":"published","subcategory":null},"questionCount":1,"sections":[{"id":"section-pathophysiology","num":"01","title":"Pathophysiology"},{"id":"section-classification-and-clinical-manifestation","num":"02","title":"Classification and Clinical Manifestation"},{"id":"section-diagnostic-workup","num":"03","title":"Diagnostic Workup"},{"id":"section-management-and-treatment","num":"04","title":"Management and Treatment"},{"id":"section-differential-diagnosis-and-distractors","num":"05","title":"Differential Diagnosis and Distractors"},{"id":"section-traps-and-high-yield-pearls","num":"06","title":"Traps and High-Yield Pearls"}],"hasSummaryTable":true}]